No ConditionNCT07320742
Fast vs. Slow Pranayama for Breathing, Heart, Balance, and Well-Being in Students
A study testing Slow Pranayama and Fast Pranayama in people with No Condition, run by Istanbul Medipol University Hospital at 1 site in Turkey (Türkiye).
Trial summary
The goal of this clinical trial is to compare the effects of slow and rapid pranayama techniques on respiratory, cardiovascular, balance, and psychosocial parameters in healthy adults aged 18-35 years. Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- No Condition
- What is being tested?
- Slow Pranayama and Fast Pranayama
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 74 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 16 Aug 2025to 5 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Between age 18-35
Who cannot join
- Subjects who have practiced yoga techniques in the last year.
- Subjects with a history of previous or current organic disease.
- Subjects who cannot practice pranayama due to physical abnormalities.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Istanbul Medipol University
Istanbul, Istanbul, 34810
About this study
Official title: Comparison of the Effects of Fast and Slow Pranayama Techniques on Respiratory, Cardiovascular, Balance, and Psychosocial Parameters in University Students
The goal of this clinical trial is to compare the effects of slow and rapid pranayama techniques on respiratory, cardiovascular, balance, and psychosocial parameters in healthy adults aged 18-35 years.
The main questions it aims to answer are:
Read more
Do slow and rapid pranayama techniques produce different improvements in lung volumes and peak cough flow?
Does slow pranayama lead to greater improvements in oxygen saturation and cardiovascular parameters, while rapid pranayama provides greater gains in balance and respiratory flow values?
Researchers will compare a slow pranayama group (n = 39) and a rapid pranayama group (n = 39) to determine how breathing speed influences physiological and psychosocial outcomes.
Participants will:
Be randomly assigned to one of two groups (slow or rapid pranayama).
Practice their assigned pranayama techniques for 25-30 minutes, 4 days per week for 12 weeks (one supervised, three home-based sessions).
Undergo pre- and post-intervention assessments including spirometry (FVC, FEV₁, FEF25%-75%, PEF), oxygen saturation, peak cough flow, blood pressure, heart rate, balance tests (single-leg stance, Y-Balance Test), and validated questionnaires for perceived stress, anxiety, depression, fatigue, and sleep quality.
This study aims to clarify how controlled breathing speed influences respiratory efficiency, cardiovascular regulation, postural stability, and mental well-being in young adults, contributing to evidence-based recommendations for integrating pranayama into stress-management and preventive rehabilitation programs.
- Conditions
- No Condition
- Being tested
- Slow Pranayama, Fast Pranayama
- Keywords
- pranayama, pulmonary function test, breathing exercise, oxygen saturation, Stress, Psychological, postural balance
- Medical subject headings
- Stress, Psychological
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Slow PranayamaBehavioural
Participants will practice pranayama in a quiet room, comfortably seated (sukhasana), maintained at a comfortable temperature (24 ± 2°C). Sessions typically take place as follows:
Participants in the Slow Pranayama Group will practice the Anuloma Viloma, Savitri, and Ujjayi breathing techniques. Slow pranayama breathing will be practiced for two minutes, with one-minute rests between each breathing technique, for a total of three cycles. Each cycle will last approximately nine minutes. Participants in both groups will rest in savasana for 10 minutes at the end of the session.
No drugs or devices are used. The intervention is a controlled breathing exercise technique.
Fast PranayamaBehavioural
Participants will practice pranayama in a quiet room, comfortably seated (sukhasana), maintained at a comfortable temperature (24 ± 2°C). Sessions will typically be conducted as follows:
Participants in the Fast Pranayama Group will practice Kapalabhati, Bhastrika, and Agnisar breathing. Each breathing technique will be practiced for one minute, followed by a one-minute rest. This will be practiced for a total of four cycles. Each cycle will last approximately six minutes.
No drugs or devices are used. The intervention is a controlled breathing exercise technique.
| Study group | Role | What they receive |
|---|---|---|
| Slow Pranayama Group | Experimental | Not described Receives: Behavioral: Slow Pranayama |
| Fast Pranayama Group | Experimental | Not described Receives: Behavioral: Fast Pranayama |
What is being measured
The primary outcome is the main question the study is designed to answer.
Forced Expiratory Flow at 25-75% of FVC (FEF25-75)
FEF25-75 is the average flow rate during the middle half of the FVC maneuver. It is often considered a sensitive indicator of small airway function. Measurements will be carried out using the COSMED PONY FX (Italy) device, ensuring compliance with ATS/ERS standards. The values will be recorded in liters per second (L/s).
Measured: From enrollment to the end of treatment at 12 weeks
Secondary outcomes (14)
Forced Vital Capacity (FVC)
Forced Vital Capacity (FVC) represents the maximum volume of air that can be forcibly expelled from the lungs after taking the deepest possible breath. Measurements will be performed in accordance with ATS/ERS guidelines. All pulmonary function measurements will be performed using a spirometer (COSMED PONY FX®, Italy). The highest value obtained from three acceptable and repeatable maneuvers will be recorded in liters (L).
Measured: From enrollment to the end of treatment at 12 weeks
Forced Expiratory Volume in 1 Second (FEV1)
FEV1 measures the volume of air exhaled during the first second of the FVC maneuver. It is a critical indicator of airway patency and respiratory muscle function. Data collection will be conducted using the COSMED PONY FX (Italy) device, following the ATS/ERS standardization guidelines. Results will be expressed in liters (L).
Measured: From enrollment to the end of treatment at 12 weeks
FEV1/FVC Ratio
This parameter represents the ratio of FEV1 to FVC, which is used to differentiate between obstructive and restrictive ventilatory patterns. The measurements will be obtained using the COSMED PONY FX (Italy) spirometer, adhering to ATS/ERS guidelines. The result is expressed as a decimal ratio or percentage.
Measured: From enrollment to the end of treatment at 12 weeks
Peak Expiratory Flow (PEF)
Peak Expiratory Flow (PEF) is the maximum flow rate achieved during a forced expiratory maneuver starting from full inspiration. It reflects the caliber of the large airways and the strength of the expiratory muscles. The measurements will be recorded using the COSMED PONY FX (Italy) spirometer according to ATS/ERS criteria, with the highest value reported in liters per second (L/s) or liters per minute (L/min).
Measured: From enrollment to the end of treatment at 12 weeks
Peak Cough Flow (PCF)
Peak cough flow (PCF) will be assessed using a handheld flow meter (Expirite® DL-F03). For all primary measurements, the highest value obtained from three replicates will be used in the analysis.
Measured: From enrollment to the end of treatment at 12 weeks.
Oxygen Saturation
It will be evaluated with a pulse oximeter (Freely SHO-3002) attached to the fingertip.
Measured: From enrollment to the end of treatment at 12 weeks
Blood Pressure
Cardiovascular parameters will be measured after participants rest in a supine position for 10 minutes. Systolic and diastolic blood pressure measurements will be taken with a non-invasive OMRON M2 Intelli IT HEM-7143T1-EBK automatic blood pressure monitor (OMRON Healthcare Europe B.V., Netherlands).
Measured: From enrollment to the end of treatment at 12 weeks
Static Balance
Static balance will be assessed using the one-leg stance test. In this test, participants will be asked to lift the foot on the tested side approximately 5 cm above the medial malleolus of the other foot while standing and maintain this position. The test will conclude when the foot touches the ground. Successful completion of the test is demonstrated by the participant's ability to maintain the position for 30 seconds. The best score from three repetitions will be recorded.
Measured: From enrollment to the end of treatment at 12 weeks
Dynamic Balance
Dynamic balance ability will be assessed with the Y Balance Test (YDT). The YDT is a frequently used dynamic test to objectively assess lower extremity function and balance. Performance on this test is quantified as a measure of maximum reach in a specific direction or as a calculated composite score (average reach across all reach directions). During the test, participants are asked to maintain balance while reaching in the anterior, posterolateral, and posteromedial directions using their right and left feet. To calculate the test score, the average reach distance in each direction is calculated in centimeters by averaging three trials for each direction. This value is then divided by the participant's leg length and multiplied by 100 to calculate the distance in each direction as a percentage.
Measured: From enrollment to the end of treatment at 12 weeks
Anxiety
Beck Anxiety Inventory (BAI) It is a 21-item, four-point Likert-type scale designed to measure an individual's anxiety severity over the past week. Each item is scored from 0 to 3. A total score between 8 and 15 indicates low anxiety; 16-25 indicates moderate anxiety; and 26-63 indicates high anxiety.
Measured: From enrollment to the end of treatment at 12 weeks
Depression
Beck Depression Inventory (BDI) The BDI is a 21-item inventory; each item represents a symptom of depression. The BDI, a self-report instrument, is the most widely used depression measurement tool worldwide. Respondents rate 21 symptoms of depression on a 4-point scale ranging from 0 to 3. Therefore, total scores range from 0 to 63, with higher scores indicating greater depression severity.
Measured: From enrollment to the end of treatment at 12 weeks
Perceived Stress
Stress level is going to evaluate with the Perceived Stress Scale (PSS), it consists of 14 items and is designed to measure the degree to which a person perceives certain life situations as stressful. Participants rate each item on a 5-point Likert-type scale ranging from "Never (0)" to "Very often (4)." Seven of the positively worded items are reverse-scored. Scores range from 0 to 56. Higher scores indicate greater perceived stress.
Measured: From enrollment to the end of treatment at 12 weeks
Fatigue Level
The Fatigue Severity Scale (FSS), consists of nine items. For each question, the patient is asked to select a number between 1 and 7 indicating how much they agree with each statement, with 1 indicating strongly disagree and 7 indicating strongly agree. A score of 4 or higher generally indicates severe fatigue.
Measured: From enrollment to the end of treatment at 12 weeks
Sleep Quality
Pittsburgh Sleep Quality Index (PSQI) The PSQI is a self-assessment tool that provides detailed information about sleep quality and the type and intensity of sleep disturbances over the past month. The index consists of 24 items, five of which are answered by the individual's sleep partner or roommate. The PSQI provides scores for seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, sleeping pill use, and daytime dysfunction. Each item is scored between 0 and 3. The sum of the scores for these seven components provides the PSQI score. The total PSQI score ranges from 0 to 21. A total score of 5 or less is considered to have "good" sleep quality, while a score above 5 indicates "poor" sleep quality. A PSQI score above 5 indicates that the individual has severe sleep problems in at least two different components or mild or moderate problems in more than three components. The sc
Measured: From enrollment to the end of treatment at 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2026
- Study start16 Aug 2025
- Primary completion21 Oct 2025
- Study completion5 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for No ConditionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 74 participants (actual)
Sponsor and investigators
- Lead sponsor
- Istanbul Medipol University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, gorkem ata, Medipol University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07320742
- Sponsor's protocol ID
- E-10840098-202.3.02-4030
- Status last verified
- Aug 2025
- First submitted
- 8 Dec 2025
- Last updated
- 24 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of the Effects of Fast and Slow Pranayama Techniques on Respiratory, Cardiovascular, Balance, and Psychosocial Parameters in University Students
- ClinicalTrials.gov ID
- NCT07320742
- Acronym / sponsor ID
- E-10840098-202.3.02-4030
- Conditions
- No Condition
- Keywords
- pranayama, pulmonary function test, breathing exercise, oxygen saturation, Stress, Psychological, postural balance
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 74 participants (actual)
- Lead sponsor
- Istanbul Medipol University HospitalUniversity, hospital or other
- Study start
- 16 Aug 2025 (actual)
- Primary completion
- 21 Oct 2025 (actual)
- Study completion
- 5 Jan 2026 (actual)
- First posted
- 6 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to compare the effects of slow and rapid pranayama techniques on respiratory, cardiovascular, balance, and psychosocial parameters in healthy adults aged 18-35 years.
The main questions it aims to answer are:
Do slow and rapid pranayama techniques produce different improvements in lung volumes and peak cough flow?
Does slow pranayama lead to greater improvements in oxygen saturation and cardiovascular parameters, while rapid pranayama provides greater gains in balance and respiratory flow values?
Researchers will compare a slow pranayama group (n = 39) and a rapid pranayama group (n = 39) to determine how breathing speed influences physiological and psychosocial outcomes.
Participants will:
Be randomly assigned to one of two groups (slow or rapid pranayama).
Practice their assigned pranayama techniques for 25-30 minutes, 4 days per week for 12 weeks (one supervised, three home-based sessions).
Undergo pre- and post-intervention assessments including spirometry (FVC, FEV₁, FEF25%-75%, PEF), oxygen saturation, peak cough flow, blood pressure, heart rate, balance tests (single-leg stance, Y-Balance Test), and validated questionnaires for perceived stress, anxiety, depression, fatigue, and sleep quality.
This study aims to clarify how controlled breathing speed influences respiratory efficiency, cardiovascular regulation, postural stability, and mental well-being in young adults, contributing to evidence-based recommendations for integrating pranayama into stress-management and preventive rehabilitation programs.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Slow Pranayama Group | Experimental | Behavioral: Slow Pranayama |
| Fast Pranayama Group | Experimental | Behavioral: Fast Pranayama |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Between age 18-35
Key exclusion criteria (3 listed)
- Subjects who have practiced yoga techniques in the last year.
- Subjects with a history of previous or current organic disease.
- Subjects who cannot practice pranayama due to physical abnormalities.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Slow PranayamaParticipants will practice pranayama in a quiet room, comfortably seated (sukhasana), maintained at a comfortable temperature (24 ± 2°C). Sessions typically take place as follows: Participants in the Slow Pranayama Group will practice the Anuloma Viloma, Savitri, and Ujjayi breathing techniques. Slow pranayama breathing will be practiced for two minutes, with one-minute rests between each breathing technique, for a total of three cycles. Each cycle will last approximately nine minutes. Participants in both groups will rest in savasana for 10 minutes at the end of the session. No drugs or devices are used. The intervention is a controlled breathing exercise technique. | Behavioural | Slow Pranayama Group |
| Fast PranayamaParticipants will practice pranayama in a quiet room, comfortably seated (sukhasana), maintained at a comfortable temperature (24 ± 2°C). Sessions will typically be conducted as follows: Participants in the Fast Pranayama Group will practice Kapalabhati, Bhastrika, and Agnisar breathing. Each breathing technique will be practiced for one minute, followed by a one-minute rest. This will be practiced for a total of four cycles. Each cycle will last approximately six minutes. No drugs or devices are used. The intervention is a controlled breathing exercise technique. | Behavioural | Fast Pranayama Group |
Primary outcome
Forced Expiratory Flow at 25-75% of FVC (FEF25-75)
Time frame: From enrollment to the end of treatment at 12 weeks
FEF25-75 is the average flow rate during the middle half of the FVC maneuver. It is often considered a sensitive indicator of small airway function. Measurements will be carried out using the COSMED PONY FX (Italy) device, ensuring compliance with ATS/ERS standards. The values will be recorded in liters per second (L/s).
14 secondary outcomes
Forced Vital Capacity (FVC)
Time frame: From enrollment to the end of treatment at 12 weeks
Forced Expiratory Volume in 1 Second (FEV1)
Time frame: From enrollment to the end of treatment at 12 weeks
FEV1/FVC Ratio
Time frame: From enrollment to the end of treatment at 12 weeks
Peak Expiratory Flow (PEF)
Time frame: From enrollment to the end of treatment at 12 weeks
Peak Cough Flow (PCF)
Time frame: From enrollment to the end of treatment at 12 weeks.
Oxygen Saturation
Time frame: From enrollment to the end of treatment at 12 weeks
Blood Pressure
Time frame: From enrollment to the end of treatment at 12 weeks
Static Balance
Time frame: From enrollment to the end of treatment at 12 weeks
Dynamic Balance
Time frame: From enrollment to the end of treatment at 12 weeks
Anxiety
Time frame: From enrollment to the end of treatment at 12 weeks
Depression
Time frame: From enrollment to the end of treatment at 12 weeks
Perceived Stress
Time frame: From enrollment to the end of treatment at 12 weeks
Fatigue Level
Time frame: From enrollment to the end of treatment at 12 weeks
Sleep Quality
Time frame: From enrollment to the end of treatment at 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for No Condition
Not yet recruiting
Autologous Thymus Transplant in Children With Congenital Heart Disease: A Pilot Study
Congenital Heart Disease (CHD)
RecruitingPhase 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
Not yet recruiting
Safety Assessment of Placing a Single Dental Implant Without Antibiotic Prophylaxis in Simple Cases: A Pilot Study
Tooth Loss and Rehabillitation, Dental Implant Failure
Not yet recruitingObservational study
Soap-and-Water Bed Bath Versus Disposable Wipe Bath in the Same ICU Patients
Critical Illness, Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Slow Pranayama and Fast Pranayama in people with No Condition, run by Istanbul Medipol University Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Forced Expiratory Flow at 25-75% of FVC (FEF25-75) (time frame: From enrollment to the end of treatment at 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.